AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced two new appointments to itsĀ Executive Committee to accelerate the advancement of its multiple therapeutic
candidates through preclinical and clinical development, thereby expanding and diversifying its pipeline.